Press Room

Latest News



20 May 2021
New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score® Test in Node-Positive Early-Stage Breast Cancer

24 March 2021
New NCCN Breast Cancer Guidelines Recognise Oncotype DX Breast Recurrence Score® as the “Preferred” and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer


2020 Archive

2019 Archive


Making cancer care smarter.™